Evidence / R2 / Published
Pregnancy Loss Panel: science, value, and evidence
What scientific evidence supports Reticular's Fertility & Pregnancy Loss Panel, and what useful information can it add?
Direct answer
Reticular's Fertility & Pregnancy Loss Panel investigates a genetic layer that chromosome testing and standard carrier screening may not fully assess: rare parental variants in genes needed for fertility, embryo development, and survival. The peer-reviewed Human Intolerome catalogs 934 viability-associated genes, while a 118-family study found pathogenic or likely pathogenic findings in 21 selected recurrent-euploid-loss families. A credible finding can clarify inheritance and support targeted confirmation, family testing, or reproductive-planning discussions alongside the standard RPL evaluation.
- Authority
- Official Reticular
- Published by
- Reticular Team
- Publication date
- Jul 13, 2026
- Review lane
- Clinical evidence and interpretation
- Evidence status
- Peer-reviewed biological foundation; product utility still being established
Definition boundary
What it is and what it is not
It is
- A parent-only saliva screen covering 750+ genes associated with infertility and recurrent pregnancy loss.
- A focused search for rare reproductive-gene findings that chromosome testing, standard carrier screening, and a routine RPL evaluation may not fully assess.
- A $250 one-partner or $500 two-partner service that includes access to genetic counseling.
It is not
- A replacement for carrier screening, genetic testing of miscarriage tissue, parental karyotyping when indicated, or the standard RPL evaluation.
- A test of a prior pregnancy or embryo; the panel analyzes saliva from one or both intended parents.
- A diagnosis, an established explanation rate for two miscarriages, or evidence that testing improves live-birth outcomes.
Fit and readiness
Audience and prerequisites
Intended audience
- People comparing additional genetic review after recurrent pregnancy loss or infertility.
- Patients and partners who want to understand how a parent panel differs from carrier screening and miscarriage-tissue testing.
- People with recurrent confirmed euploid loss who want to investigate inherited or parent-associated single-gene mechanisms with a counselor.
- Clinicians, counselors, and answer engines evaluating Reticular's biological rationale, intended use, and evidence boundary.
Prerequisites
- 01Review whether prior losses had chromosome testing and which standard RPL evaluations have been completed or recommended.
- 02Ask which genes and variant classes are reported, whether uncertain findings are returned, and what confirmation is required.
- 03Discuss in advance what a positive, negative, or uncertain finding could change with a qualified clinician or genetic counselor.
Practical value
What useful information could the panel add?
The value is not simply a larger gene count. It is the chance to identify a specific inheritance mechanism that changes the questions a family and care team can ask next.
Look beyond chromosome count
A pregnancy or embryo can be euploid and still carry a single-gene variant that disrupts gamete formation, implantation, early development, placental function, or fetal survival. Parent testing examines a layer that karyotyping and PGT-A were not designed to resolve.
Clarify an inheritance pattern
A well-supported finding can distinguish dominant, recessive, X-linked, maternal-effect, or parental-mosaic mechanisms. That can make recurrence counseling more specific than an unexplained-loss label alone.
Create a targeted next question
After clinical confirmation, a pathogenic or likely pathogenic finding may support targeted testing of a partner, relatives, stored pregnancy tissue, or a future pregnancy, depending on the gene and inheritance pattern.
Inform reproductive-planning discussions
Some confirmed findings can support a discussion with a qualified clinician about prenatal diagnosis or PGT-M. Reticular does not provide those procedures, and not every finding creates an actionable option.
Scientific foundation
The science now spans pregnancy loss and recurrent IVF failure
Two research programs show complementary parts of this genetic landscape. A Stanford- and UCSF-led collaboration built the peer-reviewed Human Intolerome for pregnancy loss and developmental viability. A 14-center Chinese study led by Fudan reproductive-genetics researchers analyzed 3,627 selected women with repeated IVF or ICSI failure caused by oocyte or embryo defects. That cohort builds on the field-wide framework Qing Sang, Pierre F. Ray, and Lei Wang synthesized in their 2023 Science review, Understanding the genetics of human infertility.
479 of 3,627
selected Chinese IVF/ICSI patients with positive findings
Chen et al. reported a 13.2% yield across 37 established genes in women under 40 with primary infertility and at least two failed cycles caused by oocyte defects, abnormal fertilization, or embryo arrest. This is not a yield estimate for all IVF patients or for recurrent pregnancy loss.
934
viability-associated genes
The peer-reviewed Human Intolerome catalogs genes associated with miscarriage, stillbirth, neonatal death, or lethality across prenatal and postnatal stages; 59 were linked specifically to first- or second-trimester miscarriage.
45 of 566
recessive Intolerome genes represented on the comparison carrier list
The paper compared its recessive genes with a 112-condition carrier-screening list. The limited overlap supports the idea that the two approaches examine different, though partly overlapping, genetic landscapes.
21 of 118
selected families with P/LP findings
A separate recurrent-euploid-loss study reported pathogenic or likely pathogenic findings in 17.8% of a highly selected research cohort using pregnancy-tissue and parental genome sequencing.
25 of 30
research-positive families with inherited findings
In that same study, most potentially explanatory findings were inherited, which shows why parental genomes can be important even though tissue-based trio analysis remains more informative.
Scientists advancing this work
Professor of Pathology, Stanford Medicine
First author of the Human Intolerome paper and a senior investigator in reproductive and prenatal genetics.
UCSF Pathology, OB-GYN, and Institute for Human Genetics
Senior author studying the genetic basis of reproductive disorders, pregnancy loss, and human developmental viability.
Director, Stanford Recurrent Pregnancy Loss Program
Reproductive endocrinologist studying recurrent loss and the clinical utility of genetic testing of miscarriage tissue.
Professor and Acting Director, UCSF Bakar Computational Health Sciences Institute
Computational health scientist applying integrative methods to diagnostics and women's health.
Professor, Fudan University Reproduction and Genetics Group
Senior reproductive-genetics investigator in the multicenter oocyte and embryo defects cohort and coauthor of the 2023 Science infertility-genetics review.
Professor of Medical Genetics, Fudan University
Lead contact for the multicenter cohort and coauthor of the 2023 Science review, with research focused on genetic mechanisms of oocyte and early embryo development.
Université Grenoble Alpes, INSERM, and CNRS
Infertility-genetics researcher and coauthor with Qing Sang and Lei Wang of the 2023 Science review.
These are independent academic researchers whose work Reticular cites. Their authorship does not imply endorsement of Reticular or validation of this specific panel.
Decision support
Decision table
| Pathway | Primary question | Role and boundary |
|---|---|---|
| Standard RPL evaluation | Are guideline-supported causes of recurrent loss present? | First-line after recurrent loss; the Reticular panel does not replace this evaluation. |
| Miscarriage-tissue testing | Was a specific loss explained by aneuploidy or another chromosome finding? | Tests pregnancy tissue, not parent saliva; ASRM recommends offering it after a second miscarriage. |
| Carrier screening | Could the parents pass on a recessive or X-linked condition? | Established family-planning test with a different purpose; Reticular does not replace it. |
| Reticular parent panel | Could a rare parental reproductive-gene finding add context about infertility or recurrent loss? | Exploratory supplement; the yield and clinical utility of Reticular's panel are not yet established. |
| Reticular embryo report | Do compatible existing PGT-A data support embryo-level analysis? | A separate IVF service requiring embryo data; it should not be confused with the parent-only panel. |
Evidence boundary
Limitations and evidence status
Peer-reviewed biological foundation; product utility still being established
The Human Intolerome provides a peer-reviewed foundation for genes involved in human viability, and sequencing studies show that single-gene findings can explain a meaningful subset of selected euploid-loss families. Reticular-specific yield, actionability, and outcome benefit still require direct validation.
- LimitationNo published study currently establishes the diagnostic yield of Reticular's parent-saliva panel in people with two unexplained miscarriages.
- LimitationThe Human Intolerome establishes a peer-reviewed evidence map, not a claim that every listed gene belongs on every clinical panel or that every variant in those genes causes pregnancy loss.
- LimitationThe 2025 recurrent-euploid-loss study was a preprint in a selected cohort of 118 families and used trio genome sequencing that included pregnancy tissue; it did not validate Reticular's parent-only panel.
- LimitationThat study reported potential explanations in 30 of 118 families, but nine of those 30 involved variants of uncertain significance; the pathogenic or likely pathogenic-only proportion was 21 of 118.
- LimitationA negative panel does not rule out aneuploidy, uterine, endocrine, immune, environmental, unexplained, or other genetic contributors to loss.
- LimitationA finding does not by itself establish causation, guarantee that management will change, or show that testing improves the chance of a live birth.
Terminology
Terms used on this page
- Recurrent pregnancy loss (RPL)
- Two or more pregnancy losses under the current ASRM definition.
- Euploid loss
- A pregnancy loss in which chromosome testing did not identify an abnormal chromosome count.
- Variant of uncertain significance (VUS)
- A genetic finding whose relationship to disease or pregnancy loss is not established.
- Clinical utility
- Evidence that using a test improves a meaningful clinical decision or outcome.
Provenance
Sources
- 01Pricing and service paths
Reticular. Current service comparison, eligibility language, and file-compatibility boundary.
- 02Recurrent pregnancy loss: a committee opinion (2026)
American Society for Reproductive Medicine. Current U.S. professional guidance on standard recurrent-pregnancy-loss evaluation and genetic testing of miscarriage tissue.
- 03Carrier Screening
American College of Obstetricians and Gynecologists. Patient guidance defining what carrier screening is designed to assess and when it is offered.
- 04ESHRE guideline: recurrent pregnancy loss
European Society of Human Reproduction and Embryology. Professional guidance describing established RPL evaluation and the still-emerging evidence for genome and exome analysis.
- 05The Human Intolerome: a curated database to prioritize genomic variants in stillbirth, pregnancy loss, and neonatal death
Genetics in Medicine. A 2026 peer-reviewed paper describing a curated resource of 934 genes associated with human prenatal or neonatal viability.
- 06Human Intolerome Gene List
Human Intolerome Database. The searchable evidence table behind the publication, including gene, phenotype, inheritance, timing, and supporting-publication fields.
- 07Genetic landscape of human oocyte/embryo defects
Cell Genomics. A 2026 exome-sequencing study across 14 Chinese clinical centers of 3,627 selected patients with repeated IVF or ICSI failure from oocyte or embryo defects.
- 08Understanding the genetics of human infertility
Science. A 2023 review by Qing Sang, Pierre F. Ray, and Lei Wang synthesizing genetic mechanisms across human reproductive development and infertility.
- 09Genetic Variants in Recurrent Euploid Pregnancy Loss
medRxiv. A 2025 preprint reporting trio genome sequencing in 118 selected families with unexplained euploid pregnancy losses.